About Aqemia
Aqemia is a biotechnology company reinventing drug discovery through the integration of generative AI and deep physics. The company operates at the intersection of technology and life sciences, developing a proprietary drug discovery pipeline that goes beyond conventional and AI-augmented approaches. Aqemia's platform leverages advanced computational chemistry, machine learning, and quantum physics to design and optimize novel drug candidates at scale. With a multidisciplinary team spanning AI, software engineering, computational chemistry, and drug discovery, Aqemia is building a portfolio of innovative therapeutics. The company maintains offices in both Paris, France and London, UK, positioning itself as a European leader in AI-driven drug discovery. Aqemia's mission-driven culture emphasizes collaboration, ownership, and meaningful impact in advancing medicines that address unmet medical needs.
Mission & Story
Mission
to invent new medicines
Who It Serves
Milestones & Awards
Recent Milestones
Participating in J.P. Morgan Healthcare Conference 2026 (January), Jefferies Global Healthcare Conference 2025 (November), and Jefferies European Disruptive Tech Conference (October 2025)
Social & Media
Follow on
Company Details
- Headquarters
- Paris, France
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Aria Pharmaceuticals
Aria Pharmaceuticals appears to be a pharmaceutical company focused on drug discovery and development. Based on the limited information available, the company operates in the pharmaceutical sector.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.